Short answer
AVITA Medical, Inc. (RCEL) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $17M (down 12.7% year over year) with net income of −$13M.
Q3 2025 key financials · XBRL
- Revenue
- $17M
- −12.7% YoY · −7.4% QoQ
- Net income
- −$13M
- +18.6% YoY · −32.9% QoQ
- Operating margin
- -53.6%
- Gross margin
- 81.3%
- EPS (diluted)
- −$0.47
- +25.4% YoY · −27.0% QoQ
Source: XBRL data from the AVITA Medical, Inc. (RCEL) Q3 2025 10-Q on SEC EDGAR. USD.
AVITA Medical, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new risk factors added this quarter; risk profile unchanged since 2024 Annual Report
- No material updates to existing risks since prior 10-K and Q1 2025 10-Q filings
- Regulatory risk carried forward includes uncertainties in product approvals and compliance with FDA requirements
- Operational risk from market adoption and competitive pressures remains critical for near-term revenue growth
- Financial risk centered on liquidity and capital resources continues without changes from prior disclosures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AVITA Medical, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.